Adiponectin, biomarkers of inflammation and changes in cardiac autonomic function: Whitehall II study

Christian Stevns Hansen1*, Dorte Vistisen1, Marit Eika Jørgensen1, Daniel R. Witte2,3, Eric J. Brunner4, Adam G. Tabák4,5, Mika Kivimäki4, Michael Roden6,7,8, Marek Malik9 and Christian Herder6,7

Abstract

Background: Biomarkers of inflammation and adiponectin are associated with cardiovascular autonomic neuropathy (CAN) in cross-sectional studies, but prospective data are scarce. This study aimed to assess the associations of biomarkers of subclinical inflammation and adiponectin with subsequent changes in heart rate (HR) and heart rate variability (HRV) in non-diabetic and diabetic individuals.

Methods: Data are based on up to 25,050 person-examinations for 8469 study participants of the Whitehall II cohort study. Measures of CAN included HR and several HRV indices. Associations between baseline serum levels of high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, IL-1 receptor antagonist (IL-1Ra) and adiponectin and 5-year changes in HR and six HRV indices were estimated using mixed-effects models adjusting for age, sex, ethnicity, body mass index (BMI), metabolic covariates and medication. A modifying effect of diabetes was tested.

Results: Higher levels of IL-1Ra were associated with higher increases in HR. Additional associations with measures of HRV were observed for hsCRP, IL-6 and IL-1Ra, but these associations were explained by BMI and other confounders. Associations between adiponectin, HR and HRV differed depending on diabetes status. Higher adiponectin levels were associated with more pronounced decreases in HR and increases in three measures of HRV reflecting both sympathetic and vagal activity, but these findings were limited to individuals with type 2 diabetes.

Conclusions: Higher IL-1Ra levels appeared as novel risk marker for increases in HR. Higher adiponectin levels were associated with a more favourable development of cardiovascular autonomic function in individuals with type 2 diabetes independently of multiple confounders.

Keywords: Cardiovascular disease, Cardiovascular autonomic neuropathy, Heart rate, Inflammation, Adipokine, Prediction
Risk factors for CAN are only partly understood. Old age, hyperglycaemia and further obesity-associated metabolic derangements contribute to the incidence of CAN, so that optimised glycaemic control and a multifactorial approach targeting cardiovascular risk factors using lifestyle-based and pharmacological strategies represent the cornerstone of current prevention guidelines [1]. However, there are currently no therapeutic options aiming at other pathomechanisms of CAN. One of the mechanisms that has been implicated in the development of CAN is subclinical inflammation [7, 8]. Higher levels of proinflammatory biomarkers of inflammation such as high-sensitivity C-reactive protein (hsCRP) and interleukin (IL)-6 have been found associated with impaired HRV and higher odds of CAN [7]. Additionally, higher rather than lower circulating levels of the insulin-sensitising and potentially atheroprotective adipokine adiponectin [9] have been shown to be associated with CAN [10] or reduced HRV [11] in patients with type 2 diabetes.

Importantly, almost all available data on the relationship between subclinical inflammation and HRV or CAN are based on cross-sectional studies which does not allow for conclusions on causality, as the direction of associations may be bidirectional (reverse causality). Given the bidirectional interaction between the autonomic nervous system and inflammation [8], and the risk of reverse causality in the association between inflammation and cardiovascular phenotypes [12], large prospective studies are needed to elucidate the temporal relationships between biomarkers of inflammation including adiponectin and CAN.

Therefore, we aimed to investigate the prospective associations of baseline levels of biomarkers of subclinical inflammation [hsCRP, IL-6, IL-1 receptor antagonist (IL-1Ra)] and adiponectin with subsequent 5-year changes in HR and HRV in individuals with and without diabetes in large cohort.

Methods
Study participants, procedures and measurements
Participants are from the Whitehall II Study, an occupational cohort of 10,308 British civil servants (6896 men and 3412 women aged 35–55 years) of mainly white ethnicity recruited between 1985 and 1988 (phase 1) [13].

The cohort has been followed at eight subsequent phases. Every second phase (~ 5 years apart) included a clinical health examination (phases 1, 3, 5, 7, and 9). Data from phases 3, 5, 7, and 9 form the basis for this study as measurements of inflammation, HR, HRV and a standard 2-h 75 g OGTT were performed at those phases. Diabetes was diagnosed at screening by OGTT (WHO criteria) or by self-reported diagnosis. Participants fasting ≥ 8 h were classified as having diabetes if fasting- or 2-h plasma glucose value were ≥ 7.0 or 11.1 mmol/l respectively. Participants fasting < 8 h were classified with diabetes if any of their two glucose measurements were ≥ 11.1 mmol/l. Blood pressure and lipids were measured as described [13]. Patients with heart disease including ischemic heart disease and arrhythmias at baseline were excluded from analyses.

During follow-up, participants were censored if they died, were lost to follow-up or developed heart disease e.g. ischemic heart disease and arrhythmias either diagnosed at study examination or by register based follow-up, which comprised 1809 (6.0%) person-examinations. Serum levels of hsCRP, IL-6, IL-1Ra and total adiponectin were measured as described [14, 15]. We excluded 543 (1.9%) person-examinations with hsCRP > 10 mg/l as indicator of acute infections.

Five-minute resting 12-lead ECG recordings were obtained subsequent to 5 min of supine rest. Recordings were filtered through an automated algorithm, allowing the analyses of suitable R–R intervals without the presence of arrhythmias, ectopic beats and branch blocks. Indices of HRV were analysed in the time domain [the standard deviation of all intervals between R waves with normal-to-normal conduction (SDNN) and the root mean square of the sum of the squares of differences between consecutive R–R intervals (RMSSD)] and by utilizing a Blackman-Tukey algorithm also in the frequency domain low-frequency (LF) power (in the 0.04–0.15 Hz frequency band), high-frequency (HF) power (in the 0.15–0.4 Hz frequency band) and total power (in the ≤ 0.4 Hz frequency band). The ratio between LF and HF power (LF/HF ratio) was calculated. Information on smoking habits, physical activity and medication use were gathered by self-administered questionnaires [13].

Statistical analysis
This analysis used HR and six HRV indices (SDNN, RMSSD, HF power, LF power, LF/HF ratio and total power) as outcomes. All except HR were log-transformed prior to analysis to fulfil the assumption of normally distributed model residuals.

The following biomarkers of subclinical inflammation were included as exposures: hsCRP, IL-6, IL-1Ra and adiponectin (all log2 transformed). Adiponectin and IL-1Ra were measured only in a case-cohort subsample nested within the Whitehall II study. [14, 15].

Up to 25,050 person-examinations for 8469 participants were analysed (9459 person-examinations for the 3421 participants in the subcohort). In each 5-year observation window of two consecutive phases, we studied the associations of baseline levels of biomarkers of subclinical inflammation and follow-up levels of the different outcomes, adjusting for baseline level of the outcome.
All analyses were adjusted for age, sex, ethnicity, study phase and diabetes (model 1). Additional adjustments included BMI and physical activity (model 2) and smoking, systolic blood pressure, total cholesterol, triglycerides, tricyclic antidepressants, diuretics and beta blockers (model 3). For all outcomes except HR, analyses were also adjusted for HR obtained as part of the HRV analyses. To compare the estimated associations across the HRV analyses, we used a complete-case approach, limiting the analyses to data with complete information on all covariates in model 3. The same individual may contribute with more than one observation to the analyses. To account for the likely correlation of repeated measurements within the same participant, we used mixed-effects models with a random intercept and a random slope for time. Individuals changing diabetes state during the study contributed with person-examinations first to the non-diabetes group and later to the diabetes group.

Since prospective studies on adiponectin and cardiovascular outcomes have indicated that the direction of the association may depend on diabetes status (positive associations between adiponectin and cardiovascular events or mortality in individuals with diabetes rather than inverse associations in non-diabetic individuals) [16], we tested for a modifying effect of diabetes on the association between HR and HRV indices with adiponectin. As sensitivity analysis, we also calculated models including interaction terms with diabetes for the three biomarkers of inflammation (i.e. hsCRP, IL-6 and IL-1Ra). To assess if body composition estimated by waist circumference instead of BMI would affect model estimates, we repeated the analyses replacing BMI with waist circumference.

Heart rate and HRV indices are highly interrelated, and the same is true for the inflammation-related biomarkers and adiponectin. Therefore, correction for multiple testing would likely inflate the risk of type II errors and was therefore not applied.

Statistical analyses were performed in R version 3.3.1 (The R Foundation for Statistical Computing) and SAS version 9.2 (SAS Institute, Cary, NC).

Results
The study population included 7769 participants at the first study phase and 5427 individuals at the last study phase. Median time between two subsequent phases was 5.4 years (25th; 75th percentiles 5.0; 5.8 years). The prevalence of diabetes increased from 3.0 to 12.8%. Serum levels of hsCRP and IL-6 increased during follow-up, while levels of IL-1Ra and adiponectin remained stable. All indices of HRV decreased over the study period (Table 1).

For hsCRP, IL-6 and IL-1Ra, we found no modifying effect of diabetes on any of the associations, therefore results are presented for the whole study sample combined, adjusting for diabetes (Table 2). Higher baseline levels of IL-1Ra were associated with larger increases in HR at all adjustment levels. Conversely, higher IL-1Ra was associated with a decrease in SDNN, LF power and total power in model 1, but effects were attenuated after further adjustment for BMI and physical activity. Higher levels of hsCRP were associated with more pronounced increases in HR, and both hsCRP and IL-6 were associated with larger decreases in the LF/HF ratio, but again these associations were partially mediated by BMI and not significant in subsequent models (Additional file 1: Table S1).

In contrast, we found a modifying effect of diabetes on the association between serum levels of total adiponectin and future changes in HR and several HRV indices. In participants with type 2 diabetes, higher levels of total adiponectin were associated with a decrease in HR and increases in values of SDNN and RMSSD (time-domain indices) and of the LF power (frequency-domain index) (Table 3). These association were not only significant after initial adjustment for age, sex, ethnicity, diabetes, HR and study phase, but remained largely unaffected by further adjustment for BMI, lifestyle factors, blood pressure, serum lipids and medication (tricyclic antidepressants, diuretics and beta blockers). In contrast, non-diabetic individuals only showed an inverse association between adiponectin and HR in model 1 (Table 3).

Adjusting for waist circumference instead of BMI did not affect model estimates (Additional file 1: Table S1 and Additional file 2: Table S2).

Discussion
This study has two major findings: (i) Higher baseline levels of hsCRP, IL-6 and IL-1Ra showed associations with larger increases in HR and decreases in several HRV indices after initial adjustment for age, sex and diabetes status. BMI represented a substantial confounder for all associations expect for the one between higher IL-1Ra levels and larger increases in HR, which remained significant in the fully adjusted model. (ii) Higher baseline adiponectin levels were association with smaller increases in HR and larger increases in HRV indices reflecting both sympathetic and vagal activity. However, these associations were present only in individuals with type 2 diabetes, but absent in the non-diabetic study population.

Biomarkers of subclinical inflammation (hsCRP, IL-6, IL-1Ra), HR and HRV
Our data on biomarkers of subclinical inflammation, HR and HRV are novel, as only two small prospective studies
that investigated the temporal relationship between hsCRP and vagal tone assessed by HRV measurement of HF power [17, 18].

We show that higher IL-1Ra levels were associated with more pronounced increases in resting HR after adjustment for a range of potentially confounding factors. Given the established link between higher resting HR and increased risk of cardiovascular outcomes (e.g. coronary heart disease, sudden cardiac death, stroke, atrial fibrillation) and mortality [19], this finding implicates cytokines of the IL-1 family in the regulation of HR and in cardiovascular risk. As antagonist of the proinflammatory cytokine IL-1β, IL-1Ra has no agonist activity of its own and is thus unlikely to impair cardiac function [20]. Higher IL-1Ra levels are related to a higher risk of cardiovascular events in population-based studies [21] and have been proposed to reflect the presence of metabolic and/or inflammation-related cardiovascular risk.

Table 1 Characteristics of the study population at each study phase

|                      | Phase 3 (1991–1993) | Phase 5 (1997–1999) | Phase 7 (2002–2004) | Phase 9 (2007–2009) |
|----------------------|---------------------|---------------------|---------------------|---------------------|
| N                    | 7769                | 6105                | 5749                | 5427                |
| Men (%)              | 69.4 (68.3; 70.4)   | 70.9 (69.8; 72.1)   | 70.5 (69.3; 71.6)   | 70.0 (68.8; 71.2)   |
| White ethnicity (%)  | 90.3 (89.6; 91.0)   | 91.8 (91.1; 92.5)   | 92.1 (91.3; 92.8)   | 91.9 (91.2; 92.6)   |
| Age (years)          | 50.0 (60.0)         | 55.6 (60.0)         | 60.8 (59.9)         | 65.5 (5.8)          |
| Height (cm)          | 171.9 (9.5)         | 172.1 (9.2)         | 171.0 (9.3)         | 170.7 (9.3)         |
| BMI (kg/m²)          | 25.3 (3.7)          | 26.1 (3.9)          | 26.5 (4.2)          | 26.7 (4.4)          |
| Waist circumference (cm) | 85.7 (11.5)  | 90.5 (11.7)         | 93.1 (12.1)         | 94.5 (12.0)         |
| Current smokers (%)  | 13.0 (12.3; 13.8)   | 9.5 (8.8; 10.3)     | 7.9 (7.2; 8.6)      | 5.5 (4.9; 6.1)      |
| Moderate to vigorous exercise (hours/week) | 2.0 (1.0; 5.0)  | 11.8 (4.8; 20.3)    | 11.5 (4.3; 20.0)    | –                   |
| Alcohol intake (units/week) | 6.0 (2.0; 14.0) | 9.0 (3.0; 20.0)     | 8.0 (3.0; 17.0)     | 7.0 (2.0; 15.0)     |
| Diabetes (%)         | 3.0 (2.6; 3.4)      | 5.6 (5.1; 6.2)      | 8.9 (8.1; 9.6)      | 12.8 (11.9; 13.7)   |

Medication

|                      | Phase 3 (1991–1993) | Phase 5 (1997–1999) | Phase 7 (2002–2004) | Phase 9 (2007–2009) |
|----------------------|---------------------|---------------------|---------------------|---------------------|
| Antihypertensive treatment (%) | 6.7 (6.2; 7.3) | 11.5 (10.7; 12.3) | 21.2 (20.1; 22.3) | 32.7 (31.4; 34.0)     |
| Lipid-lowering treatment (%) | 0.7 (0.5; 0.9) | 2.5 (2.1; 2.9)    | 9.2 (8.5; 10.0)    | 29.9 (28.7; 31.1)     |
| Tricyclic antidepressants (%)a | 1.9 (1.6; 2.2) | 2.7 (2.3; 3.1)    | 2.9 (2.5; 3.4)    | 3.5 (3.0; 4.0)        |
| Diuretics (%)         | 6.1 (5.6; 6.7)     | 3.0 (2.6; 3.5)     | 7.6 (7.0; 8.4)     | 10.8 (10.0; 11.7)     |
| Beta blockers (%)     | 0.6 (0.4; 0.8)     | 4.7 (4.2; 5.3)     | 8.0 (7.3; 8.7)     | 7.4 (6.7; 8.1)        |

Blood measurements

|                      | Phase 3 (1991–1993) | Phase 5 (1997–1999) | Phase 7 (2002–2004) | Phase 9 (2007–2009) |
|----------------------|---------------------|---------------------|---------------------|---------------------|
| Total cholesterol (mmol/l) | 6.5 (1.2)     | 5.9 (1.1)         | 5.8 (1.0)          | 5.3 (1.1)          |
| HDL cholesterol (mmol/l)   | 1.4 (0.4)     | 1.5 (0.4)         | 1.6 (0.4)          | 1.6 (0.5)          |
| LDL cholesterol (mmol/l)   | 4.4 (1.0)     | 3.9 (0.9)         | 3.6 (0.9)          | 3.1 (1.0)          |
| Triglycerides (mmol/l)     | 1.5 (1.1)     | 1.4 (0.9)         | 1.4 (0.9)          | 1.3 (0.7)          |
| Systolic blood pressure (mmHg) | 120.6 (13.6) | 123.0 (16.5)     | 128 (16.8)         | 125.7 (16.1)        |
| Diastolic blood pressure (mmHg) | 79.7 (9.4)   | 77.5 (10.6)      | 74.4 (10.4)        | 71.3 (10.2)         |
| CRP (mg/dl)              | 0.9 (0.4; 1.8) | 1.0 (0.5; 2.0)   | 1.2 (0.6; 2.4)     | –                   |
| IL-6 (pg/ml)             | 1.4 (1.0; 2.0) | 1.4 (1.0; 2.0)   | 1.7 (1.3; 2.4)     | –                   |
| IL-1Ra (pg/ml)b          | 251 (195; 329) | 340 (266; 437)   | 347 (271; 458)     | 347 (273; 450)      |
| Adiponectin (µg/ml)b     | 8.5 (6.2; 12.1) | 8.5 (6.2; 12.1)  | 8.3 (5.9; 11.9)    | 8.4 (5.8; 12.9)     |

Heart rate measurements

|                      | Phase 3 (1991–1993) | Phase 5 (1997–1999) | Phase 7 (2002–2004) | Phase 9 (2007–2009) |
|----------------------|---------------------|---------------------|---------------------|---------------------|
| Heart rate from ECG (bpm) | 64.7 (10.7)   | 67.3 (11.2)        | 67.9 (11.6)         | 66.5 (11.5)         |
| SDNN (ms)             | –                   | 34.2 (26.0; 44.8)  | 33.7 (25.4; 44.7)   | 29.8 (22.0; 40.1)   |
| RMSSD (ms)            | –                   | 20.3 (13.6; 29.4)  | 20.5 (13.6; 30.2)   | 17.5 (11.8; 26.6)   |
| Low-frequency power (ms²) | 309 (1657; 569) | 284 (157; 324)    | 222 (113; 439)      |                    |
| High-frequency power (ms²) | 128 (615; 251) | 115 (56; 236)     | 86 (42; 186)        |                    |
| LF/HF ratio           | –                   | 2.6 (1.5; 4.1)     | 2.6 (1.5; 4.0)      | 2.6 (1.6; 4.1)      |
| Total power (ms²)     | –                   | 1048 (601; 1784)   | 1004 (568; 1749)    | 779 (423; 1411)     |

Data are means (SD), medians (25th; 75th percentiles) or proportions (95% CI)

a At phase 3, we are not able to separate tricyclic antidepressants from other antidepressants

b Subsample (n = 9459 records)
Table 2: Effects (with 95% CI) of a doubling in the inflammatory marker at baseline on 5-year changes in heart rate and HRV indices

| Outcome                  | Model | hsCRP | IL-6 | IL-1Ra |
|--------------------------|-------|-------|------|--------|
|                          |       | n     | Estimate | p     | n     | Estimate | p   | n     | Estimate | p   |
| Heart rate (bpm)         | 1     | 13,251| 0.2 (0.1; 0.3) | < 0.001 | 12,971| 0.1 (0.0; 0.3) | 0.100 | 7241 | 0.7 (0.4; 1.0) | < 0.001 |
|                          | 2     | 13,251| 0.1 (0.0; 0.2) | 0.052 | 12,971| 0.0 (−0.2; 0.2) | 0.910 | 7241 | 0.6 (0.3; 1.0) | < 0.001 |
|                          | 3     | 13,251| 0.1 (0.0; 0.2) | 0.0108 | 12,971| 0.0 (−0.2; 0.1) | 0.696 | 7241 | 0.6 (0.2; 0.9) | 0.002 |
| SDNN (% diff)            | 1     | 4258 | 0.1 (−0.7; 0.9) | 0.796 | 4286 | −0.3 (−1.8; 1.3) | 0.731 | 2399 | −3.2 (−5.7; −0.6) | 0.018 |
|                          | 2     | 4258 | 0.3 (−0.6; 1.2) | 0.502 | 4286 | −0.1 (−1.6; 1.6) | 0.949 | 2399 | −2.3 (−5.0; 0.6) | 0.120 |
|                          | 3     | 4258 | 0.5 (−0.4; 1.4) | 0.267 | 4286 | 0.3 (−1.3; 1.9) | 0.750 | 2399 | −1.8 (−4.6; 1.1) | 0.225 |
| RMSSD (% diff)           | 1     | 4258 | 0.5 (−0.6; 1.7) | 0.376 | 4286 | 0.7 (−1.5; 2.8) | 0.546 | 2399 | −2.0 (−5.6; 1.7) | 0.277 |
|                          | 2     | 4258 | 0.6 (−0.7; 1.9) | 0.360 | 4286 | 0.8 (−1.5; 3.0) | 0.513 | 2399 | −1.1 (−4.9; 2.9) | 0.580 |
|                          | 3     | 4258 | 0.6 (−0.7; 1.9) | 0.354 | 4286 | 0.7 (−1.5; 3.0) | 0.529 | 2399 | −0.9 (−4.9; 3.1) | 0.644 |
| Low frequency power (% diff) | 1     | 4258 | −0.9 (−2.7; 0.9) | 0.342 | 4286 | −1.8 (−5.1; 1.6) | 0.299 | 2399 | −7.1 (−12.5; −1.4) | 0.016 |
|                          | 2     | 4258 | −0.1 (−2.1; 1.9) | 0.930 | 4286 | −0.7 (−4.2; 2.9) | 0.694 | 2399 | −3.9 (−9.8; 2.5) | 0.227 |
|                          | 3     | 4258 | 0.5 (−1.5; 2.5) | 0.645 | 4286 | 0.1 (−3.4; 3.8) | 0.937 | 2399 | −2.7 (−8.8; 3.9) | 0.420 |
| High frequency power (% diff) | 1     | 4258 | 0.6 (−1.5; 2.7) | 0.588 | 4286 | 1.3 (−2.5; 5.2) | 0.510 | 2399 | −5.2 (−11.3; 1.3) | 0.114 |
|                          | 2     | 4258 | 1.1 (−1.2; 3.4) | 0.347 | 4286 | 2.0 (−2.0; 6.1) | 0.334 | 2399 | −2.8 (−9.5; 4.3) | 0.430 |
|                          | 3     | 4258 | 1.2 (−1.1; 3.5) | 0.299 | 4286 | 2.1 (−1.9; 6.3) | 0.312 | 2399 | −2.3 (−9.1; 5.0) | 0.524 |
| LF/HF ratio (% diff)     | 1     | 4258 | −1.4 (−2.7; −0.2) | 0.027 | 4286 | −3.0 (−5.3; −0.6) | 0.013 | 2399 | −1.7 (−5.8; 2.6) | 0.433 |
|                          | 2     | 4258 | −1.2 (−2.6; 0.2) | 0.099 | 4286 | −2.6 (−5.0; −0.1) | 0.039 | 2399 | −1.0 (−5.4; 3.7) | 0.684 |
|                          | 3     | 4258 | −0.7 (−2.1; 0.7) | 0.314 | 4286 | −1.8 (−4.3; 0.7) | 0.152 | 2399 | −0.3 (−4.8; 4.5) | 0.913 |
| Total power (% diff)     | 1     | 4258 | 0.0 (−1.6; 1.6) | 0.973 | 4286 | −0.7 (−3.7; 2.3) | 0.630 | 2399 | −0.6 (−11.3; −13) | 0.015 |
|                          | 2     | 4258 | 0.5 (−13.23) | 0.596 | 4286 | −0.1 (−3.3; 3.1) | 0.939 | 2399 | −4.2 (−9.5; 1.4) | 0.142 |
|                          | 3     | 4258 | 1.0 (−0.8; 2.8) | 0.282 | 4286 | 0.7 (−2.5; 3.9) | 0.690 | 2399 | −3.2 (−8.7; 2.6) | 0.274 |

*bpm* beats per minute, *diff.* difference, *N* number of person-examinations used in the particular analysis
*p*<sub>p</sub> value for the test of the effect being equal to zero

Model 1: Adjusted for age, sex, ethnicity, study phase and diabetes. For HRV indices, further adjustment for heart rate obtained as part of the HRV analyses

Model 2: Further adjustment for BMI and physical activity

Model 3: Further adjustment for smoking, systolic blood pressure, total cholesterol, triglycerides, tricyclic antidepressants, diuretics and beta blockers
Table 3  Effects (with 95% CI) of a doubling in adiponectin at baseline on 5-year changes in heart rate and HRV indices by diabetes status

| Model | No diabetes | | Diabetes | | Pinteraction |
| --- | --- | --- | --- | --- | --- |
| | n | Estimate | p | n | Estimate | p | |
| Heart rate (bpm) | 1 | 6841 | −0.3 (−0.6; 0.0) | 0.029 | 400 | −1.5 (−2.5; −0.5) | 0.003 | 0.021 |
| | 2 | 6841 | −0.2 (−0.5; 0.1) | 0.119 | 400 | −1.4 (−2.4; −0.4) | 0.005 | 0.022 |
| | 3 | 6841 | −0.2 (−0.5; 0.2) | 0.313 | 400 | −1.3 (−2.3; −0.3) | 0.014 | 0.035 |
| SDNN (% diff.) | 1 | 2210 | 1.3 (−1.1; 3.7) | 0.287 | 189 | 10.1 (2.5; 18.2) | 0.009 | 0.027 |
| | 2 | 2210 | 0.7 (−1.7; 3.1) | 0.591 | 189 | 9.3 (1.8; 17.4) | 0.015 | 0.028 |
| | 3 | 2210 | 0.0 (−2.4; 2.5) | 0.999 | 189 | 8.2 (0.7; 16.3) | 0.032 | 0.036 |
| RMSSD (% diff.) | 1 | 2210 | 0.3 (−2.9; 3.5) | 0.877 | 189 | 13.3 (2.7; 25.0) | 0.013 | 0.018 |
| | 2 | 2210 | −0.3 (−3.6; 3.0) | 0.844 | 189 | 12.5 (2.0; 24.1) | 0.019 | 0.018 |
| | 3 | 2210 | −0.7 (−4.0; 2.7) | 0.680 | 189 | 11.8 (1.2; 23.4) | 0.027 | 0.022 |
| Low frequency power (% diff.) | 1 | 2210 | 3.2 (−2.1; 8.7) | 0.245 | 189 | 27.5 (8.7; 49.5) | 0.003 | 0.011 |
| | 2 | 2210 | 1.2 (−4.1; 6.8) | 0.660 | 189 | 24.9 (6.5; 46.5) | 0.006 | 0.012 |
| | 3 | 2210 | −0.3 (−5.7; 5.4) | 0.916 | 189 | 22.5 (4.3; 43.9) | 0.013 | 0.014 |
| All participants | | | | | | | |
| High frequency power (% diff.) | 1 | 2399 | 1.7 (−3.8; 7.6) | 0.552 | | | 0.267 |
| | 2 | 2399 | 0.1 (−5.4; 6.1) | 0.960 | | | 0.303 |
| | 3 | 2399 | −1.2 (−6.9; 4.9) | 0.696 | | | 0.199 |
| LF/HF ratio (% diff.) | 1 | 2399 | 3.2 (−0.5; 7.0) | 0.090 | | | 0.319 |
| | 2 | 2399 | 2.9 (−0.8; 6.8) | 0.130 | | | 0.314 |
| | 3 | 2399 | 2.7 (−1.2; 6.8) | 0.171 | | | 0.342 |
| Total power (% diff.) | 1 | 2399 | 4.1 (−0.5; 9.0) | 0.081 | | | 0.065 |
| | 2 | 2399 | 2.6 (−2.0; 7.5) | 0.274 | | | 0.067 |
| | 3 | 2399 | 1.1 (−3.7; 6.1) | 0.662 | | | 0.086 |

For heart rate 400 out of 7241 records were for participants with diabetes. For the HRV indices, 189 out of 2399 records were for participants with diabetes. bpm beats per minute, diff. difference, n number of person-examinations used in the particular analysis

p: p-value for the test of the effect being equal to zero

pinteraction: p-value for interaction with diabetes status

Model 1: Adjusted for age, sex, ethnicity, study phase and diabetes. For HRV indices, further adjustment for heart rate obtained as part of the HRV analyses

Model 2: Further adjustment for BMI and physical activity

Model 3: Further adjustment for smoking, systolic blood pressure, total cholesterol, triglycerides, tricyclic antidepressants, diuretics and beta blockers

Factors that may involve the activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome and increased IL-1β activity [21, 22]. Higher IL-1Ra could thus be interpreted as result of an endogenous but eventually insufficient counter-regulation.

For the three biomarkers of subclinical inflammation selected in this study, we found five significant associations with changes in various HRV indices (LF power, LF/HF ratio and total power) out of 18 associations tested. Therefore, our study provides some evidence that subclinical inflammation may precede both impaired sympathetic and vagal activity, but at the same time indicates that BMI represents a major confounder in this context. Overall, effect sizes were small and no clear pattern of associations emerged, so that we did not find a pronounced impact of baseline levels of these biomarkers on impairments in HRV in our population-based study population. Therefore, our results differ from associations between inflammation-related biomarkers and cardiac autonomic dysfunction in cross-sectional studies [7]. Moreover, we could not confirm the association between CRP levels and increases in HF power from a small prospective study [18]. Although direct effects of immune activation e.g. induced by lipopolysaccharide on HR and HRV have been demonstrated, it is important to emphasise that these studies involve acute elevations of proinflammatory cytokines that exceed circulating levels in the general population by one to two orders of magnitude [23]. Collectively, these findings raise the question whether associations between biomarkers of
Adiponectin, HR and HRV

The present study demonstrates that higher serum levels of total adiponectin were associated with beneficial changes in HR and several measures of HRV 5 years after blood sampling in patients with diabetes. The associations were present for three of the six HRV indices, SDNN, RMSSD and LF power. RMSSD is a marker of parasympathetic autonomic tone whereas SDNN and LF power are mainly sympathetic measures. This suggests that in diabetes patients adiponectin could have neuroprotective effects on both branches of the autonomic nervous system. There were no significant associations between adiponectin and changes in HR or HRV in non-diabetic individuals indicating that adiponectin may not be associated with autonomic regulation in healthy people. Reduced HRV is not only strongly associated with diabetes in the general population, but already found in youth with type 2 diabetes and in adults with prediabetes or insulin resistance [24–27]. However, further research is necessary to elucidate to what extent determinants of reduced HRV and CAN such as adiponectin and other biomarkers may depend on age and on the degree of glucose intolerance and hyperglycaemia.

We are not aware of previous prospective studies that assessed the potential link between adiponectin levels and future changes in HR or HRV. Three cross-sectional studies reported that higher adiponectin levels were associated with a reduced LF/HF ratio [28], reduced very-low-frequency (VLF) power [11] and higher odds of CAN [10] in individuals with type 2 diabetes, whereas a study based on an occupational sample (prevalence of diabetes 2.3%) observed no associations between adiponectin and HRV indices [29]. Thus, the direction of associations between adiponectin and HRV or CAN differs between these aforementioned cross-sectional studies and our prospective study. Associations between higher adiponectin levels and higher cardiovascular risk have been reported before in individuals with type 2 diabetes [16] and may be explained as counterregulatory phenomenon as discussed above for IL-1Ra [30]. The second explanation is of interest because adiponectin is upregulated by natriuretic peptides which are direct markers of coronary heart disease and could mediate such associations [31].

Our findings of favourable associations between baseline adiponectin levels and changes in both HRV and indices of HRV is in line with the inverse association between higher adiponectin levels and lower incidence of distal sensorimotor polyneuropathy in an older population-based cohort with more than half of the participants having prediabetes or type 2 diabetes [32]. However, the latter association was mediated by obesity and other confounders, whereas the association with measures of early CAN in the present study was robust to extensive adjustment.

Strengths and limitations

Strengths of this study are the large sample size, the comprehensive measurements of outcomes and exposures assessed simultaneously, the extensive adjustment for confounders, the stratification by diabetes status and the exclusion of individuals with elevated hsCRP to reduce the impact of acute inflammatory states. Importantly, the prospective design allowed us to assess the temporal association between inflammation and HRV changes, whereas associations in cross-sectional studies may be attributable to reverse causality, i.e. impact of HR and HRV on biomarkers of inflammation. Limitations include the observational design that precludes causal inferences and the selection of four pro- and anti-inflammatory biomarkers whereas others (e.g. IL-18) also merit further research. Furthermore, the study population was predominantly of European descent, so that data cannot be generalised to other ethnic groups. Also, the cohort is based on people employed as civil servants at the study start excluding e.g. unemployed people and people employed in the private sector. The study may therefore not be fully generalizable to the general population.

Conclusions

Taken together, we observed that higher IL-1Ra levels preceded larger increases in resting HR. Further analyses of hsCRP, IL-6 and IL-1Ra pointed towards BMI-dependent inverse associations with indices of HRV. Higher adiponectin levels showed associations with less pronounced increases in HR and a more favourable development of sympathetic and vagal tone in individuals with type 2 diabetes. The latter associations were absent in non-diabetic individuals, so that further studies are required to clarify in which contexts adiponectin may have therapeutically interesting properties for the long-term development of autonomic regulation.
Additional files

Additional file 1: Table S1. Effects (with 95% CI) of a doubling in the inflammatory marker at baseline on 5-year changes in heart rate and HRV indices (adjusting for waist circumference).

Additional file 2: Table S2. Effects (with 95% CI) of a doubling in adiponectin at baseline on 5-year changes in heart rate and HRV indices by diabetes status (adjusting for waist circumference).

Abbreviations
CAN: cardiovascular autonomic neuropathy; HF power: high-frequency power; HR: heart rate; HRV: heart rate variability; HsCRP: high-sensitivity C-reactive protein; IL-6: interleukin 6; IL-1Ra: interleukin 1 receptor antagonist; LF power: low-frequency power; LF/HF ratio: low frequency/high frequency power ratio; RMSSD: the root mean square of the sum of the squares of differences between consecutive R–R intervals; SDNN: the standard deviation of all intervals between R waves with normal-to-normal conduction.

Authors’ contributions
CSH, DV, EJB, AGT, MK and CH contributed to the study concept and design. DRW, EJB, AGT, MK and CH contributed the data. CSH, DV and CH planned and conducted the statistical analysis. DV conducted the statistical analysis. CSH, DV and CH drafted the paper. All authors contributed to, critically revised. All authors read and approved the final manuscript.

Acknowledgements
The authors thank all the participating civil service departments and their welfare, personnel and establishment officers; the British Occupational Health and Safety Agency; the British Council of Civil Service Unions; all participating civil servants in the Whitehall II study; and all members of the Whitehall II study team. The Whitehall II study team comprises research scientists, statisticians, study coordinators, nurses, data managers, administrative assistants and data entry staff, who made the study possible.

Competing interests
MK reports grants from the Medical Research Council (K013351), NordForsk and the US National Institutes of Health (R01 HL036310, R01 AG013196), during the conduct of the study. All other authors declare that there is no duality of interest associated with their contribution to this manuscript. The funders of the study had no role in study design, data collection, analysis, interpretation or writing of the report.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. An overview of variables used in the study is available at the Whitehall II study website: http://www.ucl.ac.uk/whitehall.

Ethics approval and consent to participate
The UK NHS Health Research Authority London-Harrow ethics committee approved the study which was conducted in accordance to the Helsinki Declaration with written informed consent from all participants.

Funding
The UK Medical Research Council (K013351), British Heart Foundation and the US National Institutes of Health (R01 HL036310, R01 AG013196) have supported collection of data in the Whitehall II study. This work was funded by the German Federal Ministry of Health; the Ministry of Innovation, Science and Research in North Rhine-Westphalia; the German Center for Diabetes Research; and the Novo Nordisk Foundation. DRW is supported by the Danish Diabetes Academy, which is funded by an unrestricted grant from the Novo Nordisk Foundation.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 20 September 2017 Accepted: 8 November 2017
Published online: 01 December 2017

References
1. Pop-Busui R, Boulton AJ, Feldman EL, Blu V, Freeman R, Malik R, Sosenko JM, Ziegler D. Diabetic Neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:136–54.
2. Papas N, Vink A, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol. 2011;7:682–90.
3. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vink A, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–93.
4. Wheeler SG, Ahroni JH, Boyko EJ. Prospective study of autonomic neuropathy as a predictor of mortality in patients with diabetes. Diabetes Res Clin Pract. 2002;58:131–8.
5. Ziegler D, Zentai CP, Pers S, Rathmann W, Haastert B, Doring A, Meisinger C. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care. 2008;31:556–61.
6. Ziegler D, Voss A, Rathmann W, Strom A, Pers S, Roden M, Peters A, Meisinger C. Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey. Diabetologia. 2015;58:1118–28.
7. Haensel A, Mills PJ, Nelesen RA, Ziegler MG, Dimsdale JE. The relationship between heart rate variability and inflammatory markers in cardiovascular diseases. Psychoneuroendocrinology. 2008;33:1305–12.
8. Vink AJ, Erbas T, Caselini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4:4–18.
9. Ye R, Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab. 2013;2:133–41.
10. Jung CH, Kim BY, Kim CH, Kang SK, Jung SH, Mok JO. Association of serum adipocytokine levels with cardiac autonomic neuropathy in type 2 diabetic patients. Cardiovasc Diabetol. 2012;11:24.
11. Herder C, Schamarek I, Nowotny B, Carstensen-Kirberg M, Strassburger K, Nowotny P, Kannenberg JM, Strom A, Puttgen S, Mussig K, et al. Inflammatory markers are associated with cardiac autonomic dysfunction in recent-onset type 2 diabetes. Heart. 2017;103:63–70.
12. Sattar N, Preiss D. Reverse causality in cardiovascular epidemiological research: more common than imagined? Circulation. 2017;135:2369–72.
13. Marzioni M, Brunner EJ. Cohort profile: the Whitehall II study. Int J Epidemiol. 2005;34:251–6.
14. Carstensen M, Herder C, Kivimaki M, Jokela M, Roden M, Shipley MJ, Witte DR, Brunner EJ, Tabak AG. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes. 2010;59:1222–7.
15. Tabak AG, Carstensen M, Witte DR, Brunner EJ, Shipley MJ, Jokela M, Roden M, Kivimaki M, Herder C. Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study. Diabetes Care. 2012;35:2540–7.
16. Schottker B, Herder C, Rothenbacher D, Roden M, Kolb H, Muller H, Brenner H. Proinflammatory cytokines, adiponectin, and increased risk of primary cardiovascular events in diabetic patients with or without renal dysfunction: results from the ESTHER study. Diabetes Care. 2013;36:1703–11.

17. Jarzok WN, Koenig J, Mauris D, Fischer JE, Thayer JF. Lower heart rate variability predicts increased level of C-reactive protein 4 years later in healthy, non-smoking adults. J Intern Med. 2014;276:667–71.

18. Singh P, Hawkley LC, McCabe TW, Cacioppo JT, Mas CM. Autonomic tone and C-reactive protein: a prospective population-based study. Clin Auton Res. 2009;19:367–74.

19. Aune D, Sen A, o’Haraigh B, Janszky I, Romundstad PR, Tonstad S, Vatten L. Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality—a systematic review and dose-response meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2017;27:504–17.

20. Herder C, Donath MY. Interleukin-1 receptor antagonist: friend or foe to the heart? Lancet Diabetes Endocrinol. 2015;3:228–9.

21. Herder C, de Las Heras Gala T, Carstensen-Kirberg M, Huth C, Zierer A, Wahl S, Sudduth-Klinger J, Kualasmaa K, Peretz D, Lighthart S, et al. Circulating levels of interleukin 1-receptor antagonist and risk of cardiovascular disease: meta-analysis of six population-based cohorts. Arterioscler Thromb Vasc Biol. 2017;37:1222–7.

22. Herder C, Dalmas E, Boni-Schnetzler M, Donath MY. The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol Metab. 2015;26:551–63.

23. Hertlitz GN, Arlow RL, Cheung NH, Coyle SM, Griffel B, Macor MA, Lowry SF, Calvano SE, Gale SC. Physiologic variability at the verge of systemic inflammation: multiscale entropy of heart rate variability is affected by very low doses of endotoxin. Shock. 2015;43:133–9.

24. Aburawi EH, AlKaabi J, Zoubidi T, Shehab A, Lessan N, Al Essa A, Yasin J, Saadi H, Souid AK. Subclinical inflammation and endothelial dysfunction in young patients with diabetes: a study from united arab emirates. PLoS ONE. 2016;11:e0159808.

25. Meyer ML, Gotman NM, Soliman EZ, Whitsel EA, Arens R, Cai J, Daviglus ML, Denes P, Gonzalez HM, Moreiras J, et al. Association of glucose homeostasis measures with heart rate variability among Hispanic/Latino adults without diabetes: the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Cardiovasc Diabetol. 2016;15:45.

26. Svensson MK, Lindmark S, Wiklund U, Rask P, Karlsson M, Myrén J, Pullberg J, Johansson L, Eriksson JW. Alterations in heart rate variability during everyday life are linked to insulin resistance. A role of dominating sympathetic over parasympathetic nerve activity? Cardiovasc Diabetol. 2016;15:91.

27. Tifkincioglu BI, Bilgin S, Dukas T, Kose S, Zorlu Y. Autonomic neuropathy and endothelial dysfunction in patients with impaired glucose tolerance or type 2 diabetes mellitus. Medicine (Baltimore). 2016;95:e3340.

28. Wakabayashi S, Aso Y. Adiponectin concentrations in sera from patients with type 2 diabetes are negatively associated with sympathovagal balance as evaluated by power spectral analysis of heart rate variation. Diabetes Care. 2004;27:2392–7.

29. Charles LE, Burchfiel CM, Sarkisiyan K, Li S, Miller DB, Gu JK, Fekedulegn D, Violanti JM, Andrew ME. Leptin, adiponectin, and heart rate variability among police officers. Am J Hum Biol. 2014;27:184–91.

30. Kizer JR. Adiponectin, cardiovascular disease, and mortality: parsing the dual prognostic implications of a complex adipokine. Metabolism. 2014;63:1079–83.

31. Antonopoulos AS, Margaritis M, Coutinho P, Digby J, Patel R, Piasinos C, Ntusi N, Karamitos TD, Lee R, De Silva R, et al. Reciprocal effects of systemic inflammation and brain natriuretic peptide on adiponectin biosynthesis in adipose tissue of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 2014;34:2151–9.

32. Herder C, Kannenberg JM, Huth C, Carstensen-Kirberg M, Rathmann W, Koenig W, Heier M, Puttgren S, Thoraod B, Peters A, et al. Proinflammatory cytokines predict the incidence and progression of distal sensorimotor polyneuropathy: KORA F4/FF4 Study. Diabetes Care. 2017;40:569–79.